drugset / Trial / NCT02604368

A Sickle CEll Disease ComplicatioN Trial

NCT02604368

Phase 3 Unknown 210 enrolled Micelle BioPharma Inc
RandomizedParallel-groupTriple-blindTreatment

Summary

The objective of this study is to assess the efficacy of SC411 in reducing the number of sickle cell crisis (SCC) events in sickle cell disease (SCD) subjects receiving SC411 compared to those subjects receiving placebo.

Timeline

Start
2019-03
Primary completion
2020-12
Completion
2020-12

Drugs

EvaluationDrugModalityDoseRoute
Subject DOCONEXENT Other / unclassified Oral

Indications